Envista (NYSE:NVST) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Envista (NYSE:NVST) had its price objective lifted by Jefferies Financial Group from $20.00 to $22.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has a hold rating on the stock.

A number of other research firms have also weighed in on NVST. Leerink Partners upgraded shares of Envista from an “underperform” rating to a “market perform” rating and upped their target price for the stock from $16.00 to $23.00 in a research note on Thursday, October 31st. Piper Sandler increased their price objective on shares of Envista from $16.00 to $17.00 and gave the company a “neutral” rating in a research report on Thursday, October 31st. Leerink Partnrs raised shares of Envista from a “strong sell” rating to a “hold” rating in a research report on Thursday, October 31st. Needham & Company LLC reissued a “hold” rating on shares of Envista in a report on Thursday, October 31st. Finally, Wells Fargo & Company assumed coverage on Envista in a report on Tuesday, October 8th. They set an “equal weight” rating and a $20.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $20.13.

Envista Trading Up 0.7 %

Shares of NVST stock opened at $21.44 on Thursday. The stock has a market capitalization of $3.69 billion, a P/E ratio of -2.76, a price-to-earnings-growth ratio of 1.88 and a beta of 1.33. Envista has a fifty-two week low of $15.15 and a fifty-two week high of $24.79. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.77 and a current ratio of 2.08. The company has a 50 day moving average price of $20.03 and a 200 day moving average price of $18.83.

Envista (NYSE:NVST) last announced its quarterly earnings data on Wednesday, October 30th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.03. Envista had a positive return on equity of 3.76% and a negative net margin of 53.42%. The business had revenue of $601.00 million for the quarter, compared to analysts’ expectations of $590.34 million. During the same period last year, the firm earned $0.43 earnings per share. The company’s revenue for the quarter was down 4.8% compared to the same quarter last year. Equities research analysts predict that Envista will post 0.72 EPS for the current fiscal year.

Institutional Investors Weigh In On Envista

Several large investors have recently modified their holdings of NVST. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Envista during the 3rd quarter worth $31,000. GAMMA Investing LLC boosted its stake in shares of Envista by 69.8% during the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock worth $35,000 after buying an additional 726 shares during the period. Huntington National Bank grew its holdings in shares of Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock worth $38,000 after buying an additional 949 shares during the last quarter. Blue Trust Inc. increased its position in Envista by 69.7% in the 3rd quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its stake in Envista by 50.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after acquiring an additional 728 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.